Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Perisylvian epileptic network revisited

    Research output: Contribution to journalReviewResearchpeer-review

  2. Chronic hyponatremia - Why care? A case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Visual field defects after temporal lobe resection for epilepsy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Unexpected marked seizure improvement in paediatric epilepsy surgery candidates

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Do patients need to stay in bed all day in the Epilepsy Monitoring Unit? Safety data from a non-restrictive setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chronic hyponatremia - Why care? A case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. UGT polymorphisms and lamotrigine clearance during pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Transitorisk epileptisk amnesi

    Research output: Contribution to journalJournal articleResearch

  5. Automated differentiation between epileptic and nonepileptic convulsive seizures

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Eslicarbazepine acetate (ESL) is indicated for treatment of focal epilepsy. Our aim was to evaluate the effect and tolerability of ESL in elderly and younger adults. The primary objective was to measure changes in seizure frequency before and after at least six months of treatment. Secondary objective was to analyse the safety profile. Sub-analysis was performed in patients previously treated with oxcarbamazepine.

METHOD: A single-centre, retrospective study of patients with focal epilepsy treated with ESL. Data were collected by reviewing the clinical and laboratory files. Seventy-two patients received ESL, of which 14 were ≥60 years old, and were analysed for adverse effects. Fifty-nine patients received treatment for ≥6 months and were included in the evaluation of seizure frequency; in this group 12 were ≥60 years old.

RESULTS: Seizure frequency (n=59) was reduced for both young adults (< 60years) and elderly adults (≥60); both groups achieved better seizure control from an average of 2 to 0.5 (p-value: 0.002) and 3.5 to 0.65 (p-value:<0.05) seizures per month, respectively. Adverse effects leading to treatment discontinuation (n=72) were more frequent in elderly (42.9%) than in young adults (17.2%) (p-value 0.04). There was no significant difference in mild adverse effects between young (15.5%) and elderly adults (14.3%). Most common adverse effects were somnolence, gastrointestinal disturbances and dizziness.

CONCLUSIONS: The study indicates that ESL has an advantageous profile in relation to seizure control. The discontinuation rate might be higher in elderly than in younger adults. Further prospective studies are needed to confirm these conclusions.

Original languageEnglish
JournalSeizure
Volume53
Pages (from-to)94-99
Number of pages6
ISSN1059-1311
DOIs
Publication statusPublished - 2017

    Research areas

  • Journal Article

ID: 52659782